Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe the mechanics of E-Cigarette withdrawal to find better quit strategies

NCT ID NCT06066996

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates what happens when exclusive e-cigarette users stop vaping, focusing on withdrawal symptoms like cravings, mood changes, and sleep disruption. Researchers will give participants either a nicotine patch or a placebo patch to see how nicotine affects these symptoms. The goal is to better understand the withdrawal process and identify targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transdermal nicotine patch or placebo patch
What this could lead to
If successful, this research could identify specific targets for helping people quit e-cigarettes by managing withdrawal symptoms.
What could go wrong
This is an early-phase study focused on understanding withdrawal, not testing a treatment. Results may not lead to practical interventions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. 21-55 years old 2. good general health as reviewed by study medical team 3. vital signs in normal range as reviewed by study medical team 4. negative urine test for illicit drug use (excluding THC) and negative breath alcohol test 5. daily use of a nicotine-containing e-cigarette for at least 6 months 6. no regular use of other tobacco products (e.g., smokeless products) for at least 6 months 7. urine cotinine \>100ng/mL (i.e., recommended cutoff for confirming current nicotine use) 8. exhaled breath carbon monoxide (CO) \<6ppm 9. Penn State E-cigarette Dependence (PSED) score \>=4, indicating mild dependence or greater 10. have an interest in reducing e-cigarette use Exclusion criteria: 1. psychoactive drug use (aside from cannabis, nicotine, alcohol, caffeine) in past month 2. current use of over-the-counter (OTC) or prescription medications that may impact safety 3. use cannabis \>2 times per week 4. history of or current significant medical condition that would impact participation or safety according to the study investigators and medical staff 5. current psychiatric condition or substance use disorder (aside from tobacco use disorder) that would impact participation or safety according to the study investigators and medical staff 6. enrollment in another trial 7. positive pregnancy test 8. currently using a nicotine/tobacco cessation product 9. seizure disorder or traumatic brain injury (TBI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for E-cigarette use are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

substance withdrawal syndrome Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

E-cigarette use Withdrawal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Behavioral Pharmacology Research Unit

    RECRUITING

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.